Insilico delivers second preclinical candidate compound (PCC) to Fosun Pharma

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully delivered the second preclinical candidate compound (PCC) in its collaboration with Fosun Pharma in June 2024, a potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors. Insilico expects to submit the pre-IND application for this candidate with the CDE in 2024 Q4.

When initiating the collaboration, Fosun Pharma proposed four targets of interest, and the target of the PCC nominated in this program is one of them and plays a critical role in DNA damage repair mechanisms. Insilico’s R&D team fully analyzed and validated the target through PandaOmics, an AI target identification engine, in combination with Life Star 1, an AI-driven robotics lab. Then, scientists utilized Chemistry42, a generative chemistry engine, to generate and design compounds from scratch for the specified target.

In preclinical studies, the candidate demonstrated good selectivity, robust anti-tumor efficacy as well as promising ADMET properties. The preclinical data of this program has been recognized by Fosun Pharma and meets both parties’ criteria for PCC nomination. Insilico will advance the candidate to the IND-enabling stage and then Fosun Pharma will take over for further research and exploration.